Processing...
Clinical Trials for Colon Cancer
Search
Search
There are 245 active trials for advanced/metastatic colon cancer.
Click on a trial to see more information.
245 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with unresectable locally advanced or metastatic solid tumors who have exhausted, cannot tolerate, or lack standard treatment options receive MRG007 (ARR-217), an investigational antibody–drug conjugate targeting CDH17 and carrying the cytotoxic payload exatecan. Patients must have measurable disease, ECOG performance status 0–1, and tumor tissue available for CDH17 testing or be willing to undergo biopsy.
ClinicalTrials.gov ID: NCT07066657
TrialFetch AI summary: Patients with advanced or metastatic MSS/MSI-L colorectal cancer who have received at least one prior standard systemic therapy, and applicable targeted therapy for actionable alterations, receive intravenous CBI-1214. This investigational bispecific T-cell engager binds LY6G6D on tumor cells and CD3 on T cells to promote tumor killing.
ClinicalTrials.gov ID: NCT07321106
TrialFetch AI summary: For patients with unresectable locally advanced or metastatic KRAS-mutated or KRAS-amplified solid tumors who have received, are ineligible for, or decline standard care, this study evaluates BMS-986523 alone or with pembrolizumab, cetuximab, or gemcitabine plus nab-paclitaxel. BMS-986523 is an investigational protein-degradation therapy with an undisclosed target; the pembrolizumab arm additionally requires PD-L1 expression ≥50%.
ClinicalTrials.gov ID: NCT07223047
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors who lack effective standard treatment receive intravenous JMT108, initially every 2 weeks, in dose-escalation and tumor-specific expansion cohorts. JMT108 is an investigational PD-1–targeted antibody–IL-15 fusion protein designed to block PD-1 and deliver IL-15 signaling preferentially to PD-1–positive immune cells.
ClinicalTrials.gov ID: NCT07317505
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors harboring any KRAS mutation or wild-type KRAS amplification receive intravenous PT0511, an investigational pan-KRAS protein degrader. A colorectal cancer expansion cohort receives PT0511 plus cetuximab, an anti-EGFR antibody.
ClinicalTrials.gov ID: NCT07300150
TrialFetch AI summary: Adults with progressing relapsed or refractory, locally advanced inoperable or metastatic CRPC, colorectal, lung, head and neck, gynecologic, triple-negative breast, or esophageal squamous cell cancer receive 177Lu-BetaBart in a single-arm dose-escalation and expansion study. This investigational lutetium-177–labeled antibody targets B7-H3 (CD276) to deliver radiation to tumors.
ClinicalTrials.gov ID: NCT07189871
TrialFetch AI summary: Adults with unresectable, metastatic, or recurrent dMMR/MSI-H solid tumors receive oral GSK5460025 monotherapy, an investigational nucleotide excision repair–targeting agent that causes repair-pathway-dependent DNA damage. Dose expansion is limited to colorectal or endometrial cancer after 1–3 systemic therapy lines, including an immune checkpoint inhibitor.
ClinicalTrials.gov ID: NCT07213609
TrialFetch AI summary: Adults with ECOG 0–1 and locally advanced/metastatic solid tumors, including ER+/HER2− breast cancer, NSCLC, CRPC, and MSS colorectal cancer after prior standard therapy, receive oral IDE574 monotherapy; breast cancer cohorts require prior endocrine therapy and CDK4/6 inhibitor. ER+/HER2− breast cancer patients may receive IDE574, an investigational dual KAT6/KAT7 epigenetic inhibitor, in combination with fulvestrant.
ClinicalTrials.gov ID: NCT07540572
TrialFetch AI summary: Adults with locally advanced or metastatic solid tumors refractory to standard therapy or without proven effective options receive KIVU-107, an investigational PTK7-directed antibody-drug conjugate carrying an exatecan/topoisomerase I inhibitor payload. The study includes dose escalation followed by expansion at the recommended dose, with eligibility requiring measurable disease, ECOG 0–1, and adequate organ function.
ClinicalTrials.gov ID: NCT07229313
TrialFetch AI summary: Adults with ECOG 0–1 and measurable locally advanced/metastatic solid tumors co-expressing B7-H3 and PTK7, after progression/intolerance to prior therapy or lacking standard options, including NSCLC, ESCC, endometrial, ovarian, HNSCC, TNBC, colorectal, and CRPC. All participants receive IDE034, an investigational bispecific B7-H3/PTK7 antibody–drug conjugate with a topoisomerase I inhibitor payload, in dose-escalation and expansion cohorts.
ClinicalTrials.gov ID: NCT07503808